DrugPatentWatch Database Preview
Drugs in Development Information for Tandutinib
» See Plans and Pricing
What is the drug development status for Tandutinib?
Tandutinib is an investigational drug.
There have been 6 clinical trials for Tandutinib.
The most recent clinical trial was a Phase 2 trial, which was initiated on October 1st 2006.
The most common disease conditions in clinical trials are Glioblastoma, Gliosarcoma, and Leukemia, Myeloid, Acute. The leading clinical trial sponsors are National Cancer Institute (NCI), Millennium Pharmaceuticals, Inc., and [disabled in preview].
Summary for Tandutinib
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 1,777 |
| WIPO Patent Applications | 1,293 |
| Japanese Patent Applications | 599 |
| Clinical Trial Progress | Phase 2 (2006-10-01) |
| Vendors | 82 |
Recent Clinical Trials for Tandutinib
| Title | Sponsor | Phase |
|---|---|---|
| Safety Study of the Combination of Tandutinib With Temozolomide and Bevacizumab After Radiation and Temozolomide in Patients With Newly Diagnosed With Glioblastoma Multiforme | Millennium Pharmaceuticals, Inc. | Phase 1 |
| Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors | National Cancer Institute (NCI) | Phase 2 |
| Tandutinib in Treating Patients With Recurrent or Progressive Glioblastoma | National Cancer Institute (NCI) | Phase 1/Phase 2 |
Clinical Trial Summary for Tandutinib
Top disease conditions for Tandutinib
Top clinical trial sponsors for Tandutinib
US Patents for Tandutinib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
